Purinostat mesylate is a selective HDAC inhibitor. purinostat mesylate inhibits type I and type IIb HDACs (IC50: 0.81-11.5 nM). purinostat mesylate affects the cell cycle of LAMA84 and 188 BL-2 cells and induces apoptosis, showing a strong anti-leukaemic effect in vivo. purinostat mesylate has been used to study lymphocytic leukaemia. Purinostat mesylate can be used to study lymphocytic leukaemia.

HDAC9:622 nM, HDAC11:3349 nM, HDAC7:590 nM, HDAC10:1.1 nM, HDAC2:1.4 nM, HDAC5:426 nM, HDAC6:11.5 nM, HDAC1:0.81 nM, HDAC8:3.8 nM, HDAC3:1.7 nM, HDAC4:1072 nM